Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Regeneron pharmaceuticals, inc. crawled time : 20:20 save search
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.11%
H: 0.32%
C: -0.07%
response
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
| Email alert
Add to watchlist
trial potential
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
Published: 2023-10-22 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.21%
H: 0.08%
C: -1.81%
dupixent children year one results show
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Published: 2023-10-22 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.21%
H: 0.08%
C: -1.81%
dupixent children year one results show
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
Published: 2023-07-29 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
| Email alert
Add to watchlist
macular trial results diabetic
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
Published: 2023-05-21 (Crawled : 20:20) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.44%
H: 0.75%
C: -1.43%
dupixent copd results
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
Published: 2023-05-21 (Crawled : 20:20) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.44%
H: 0.75%
C: -1.43%
dupixent copd results
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Published: 2022-02-26 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
dupixent urticaria phase 3 hiv
Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
Published: 2022-02-26 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
dupixent
New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma
Published: 2021-12-11 (Crawled : 20:20) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
regn5458 phase 1
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.